share_log
Breakings ·  Sep 3 20:03
Cogent Biosciences Announces Phase 3 Peak Trial in Patients With Gastrointestinal Stromal Tumors (Gist) Has Completed Enrollment and Advanced Past Interim Futility Analysis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment